1 (tie), Hannah Green, Yealimi Noh and Rio Takeda, .79%. 4 (tie), Nelly Korda, Nanna Koerstz Madsen and Haeran Ryu, .78%. 7, 4 tied with .77%.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration ...

Peter Landers is The Wall Street Journal's Asia business, finance and economics editor, based in Singapore. He previously served as Tokyo bureau chief for a decade.

Clinical academia is on a steep decline globally. In the UK, a 6% reduction in the number of clinical academics since 2012 has been reported, with the number of senior lecturer level researchers ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

Pediatric patients with short bowel syndrome‐associated intestinal failure showed improvements in stool consistency and ...

Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Preetika Rana is an award-winning reporter for The Wall Street Journal in San Francisco with experience reporting from six ...

Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 7.02%, which has investors questioning if this is right time ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”) announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) ...